Justin Chakma - Nov 25, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Nov 25, 2024
Transactions value $
-$1,411,742
Form type
4
Date filed
11/27/2024, 04:11 PM
Previous filing
Jan 4, 2024
Next filing
Dec 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Sale -$459K -32.8K -13.88% $14.00 204K Nov 25, 2024 Direct F1
transaction SPRY Common Stock Sale -$593K -42.2K -20.72% $14.05 161K Nov 26, 2024 Direct F2
transaction SPRY Common Stock Sale -$360K -25K -15.49% $14.39 136K Nov 27, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.